Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

This study is testing a medication called tirzepatide (a GLP-1/GIP receptor agonist, the same type of drug as Mounjaro) in people with Crohn's disease whose symptoms have not improved despite trying multiple standard treatments. Researchers want to see whether this drug can reduce gut inflammation through a different pathway than current therapies. **You may be eligible if...** - You are between 18 and 80 years old - You have a confirmed diagnosis of Crohn's disease affecting the small intestine or large intestine, with active ulcers seen on colonoscopy - Your Crohn's has not responded well to at least 2 different advanced medications (such as biologics like infliximab, vedolizumab, or ustekinumab, or a JAK inhibitor) - If you have had bowel surgery, it must have been at least 6 months ago **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have type 1 or type 2 diabetes, or take blood sugar-lowering medication - Your BMI is below 25 - You have a personal or family history of a specific type of thyroid cancer (medullary thyroid carcinoma) or multiple endocrine neoplasia - You have ulcerative colitis or another type of inflammatory bowel disease - You are currently on steroids - You have had recent intestinal surgery (within the past 6 months) Talk to your doctor to see if this trial is right for you.